Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/INNOCARE-PHARMA-LIMITED-105526513/news/InnoCare-Pharma-Limited-gibt-die-Zulassung-der-klinischen-Studie-des-BCL2-Inhibitors-ICP-248-in-Komb-46156884/?utm_source=whatsapp&utm_medium=social&utm_campaign=share